Data to Feature New Health Economic Outcomes Research of Treatment of Emergency Department Patients with Opioid-Induced Constipation
– Bausch Health Companies Inc. (NYSETSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals, (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that new Health Economic Outcomes Research (HEOR) data featuring RELISTOR (methylnaltrexone bromide) will be shared at PAINWeek 2021 taking place in Las Vegas from Sept. 7-11, 2021 .
“We look forward to PAINWeek where we will share new HEOR data regarding the use of RELISTOR, which is approved for the treatment of opioid-induced constipation, in the hospital emergency department setting. The three abstracts presented at PAINWeek represent the broad utilization of RELISTOR in the various settings of care in which OIC patients visit,” said Robert Spurr , president, Salix Pharmaceuticals.
The following abstracts are available online via the PAINWeek website , and the corresponding scientific posters will be displayed in the exhibit hall at The Cosmopolitan of Las Vegas from Sept. 8-10, 2021 :
- Peacock, Frank et al. “Approved OIC medication use in emergency department patients with opioid-induced constipation.”
- Shah, Eric et al. “Repeat dosing with subcutaneous methylnaltrexone: a pooled analysis of up to 7 doses in patients with and without cancer.”
...
Read Full Story: https://investingnews.com/news/medical-device-investing/salix-will-share-relistor%C2%AE-data-at-painweek-2021/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.